title: Neuromuscular effects of pipecuronium bromide.
abstract: The neuromuscular effects of pipecuronium bromide have been evaluated in 90 adult patients anaesthetized with thiopentone, nitrous oxide in oxygen and intravenous fentanyl with or without halothane. Eighty patients received pipecuronium 45 micrograms kg-1 and the remaining ten 70 micrograms kg-1. A separate group of 10 patients received pancuronium in a dose of 60 micrograms kg-1 (equipotent to pipecuronium 45 micrograms kg-1). Neuromuscular block was measured using a single-twitch or train-of-four mode of stimulation. The time to onset of maximum block with pipecuronium 45 micrograms kg-1 varied between 3.5 and 5.7 min depending on the mode of stimulation and the anaesthetic technique used. The time to 25% recovery of this dose varied between 41 and 54 min. The recovery index (time from 25 to 75% recovery) averaged 29 min. These values were generally similar in the group receiving pancuronium 60 micrograms kg-1. The time to onset of complete block with 70 micrograms kg-1 of pipecuronium averaged 2.5 min and the duration to 25% recovery 95 min. There were no significant changes in heart rate and arterial pressure with the use of pipecuronium. The results show pipecuronium to be a drug resembling pancuronium in its neuromuscular effects when used in equipotent doses.
authors.affiliation: Department of Clinical Anaesthesia, Royal Victoria Hospital, Belfast, N. Ireland.
authors.forename: J C
authors.initials: JC
authors.lastname: Stanley
authors.forename: R K
authors.initials: RK
authors.lastname: Mirakhur
authors.forename: P F
authors.initials: PF
authors.lastname: Bell
authors.forename: T D
authors.initials: TD
authors.lastname: Sharpe
authors.forename: R S
authors.initials: RS
authors.lastname: Clarke
mesh_terms: D000328:Adult; D015113:Androstane-3,17-diol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000768:Anesthesia, General; D000769:Anesthesia, Inhalation; D005260:Female; D005283:Fentanyl; D006221:Halothane; D006801:Humans; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000494:pharmacology*; D009469:Neuromuscular Junction / Q000187:drug effects*; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage / Q000494:pharmacology*; D010197:Pancuronium / Q000494:pharmacology; D017300:Pipecuronium; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors; D014459:Ulnar Nerve / Q000187:drug effects / Q000502:physiology
chemical_list: D009125:Muscle Relaxants, Central; D003473:Neuromuscular Nondepolarizing Agents; D010879:Piperazines; D017300:Pipecuronium; D015113:Androstane-3,17-diol; D010197:Pancuronium; D005283:Fentanyl; D006221:Halothane